Update shared on24 Sep 2025
Fair value Decreased 30%A significant reduction in consensus revenue growth forecasts has driven the analyst price target for Allurion Technologies down from $8.38 to $5.83.
What's in the News
- Allurion Technologies was unable to file its next 10-Q by the required SEC deadline.
- The company announced a strategic Canadian distribution partnership with Minogue Medical Inc., aimed at expanding access to its metabolically focused weight loss program and integrating GLP-1 therapy.
- Allurion submitted the final module of its Pre-Market Approval application to the FDA and reported positive, supportive results from its AUDACITY Study, which met co-primary endpoints and demonstrated superior weight loss versus controls at 48 weeks.
Valuation Changes
Summary of Valuation Changes for Allurion Technologies
- The Consensus Analyst Price Target has significantly fallen from $8.38 to $5.83.
- The Consensus Revenue Growth forecasts for Allurion Technologies has significantly fallen from 14.7% per annum to 10.1% per annum.
- The Future P/E for Allurion Technologies has significantly fallen from 30.45x to 23.94x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.